Navigation Links
FDA Approves PRE-PEN Penicillin Allergy Test
Date:9/30/2009

ALK-Abelló, Inc., and AllerQuest, LLC, are pleased to announce the return of PRE-PEN® penicillin allergy skin testing products to the market. PRE-PEN® received full FDA approval on September 18, 2009. ALK-Abelló has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN®.

Round Rock, TX (PRWEB) September 30, 2009 -- ALK-Abelló, Inc., and AllerQuest, LLC, are pleased to announce the return of PRE-PEN® to the market. Under the terms of the agreement, ALK will be the exclusive distributor of PRE-PEN®. PRE-PEN® received full FDA approval on September 18, 2009.

ALK-Abelló has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN® penicillin skin testing products. AllerQuest will manufacture the product in their FDA approved production facility in Plainville, Connecticut.

PRE-PEN® was a widely used skin test product for more than 30 years. In 2004, PRE-PEN® was withdrawn from the marketplace due to the lack of a dedicated penicillin manufacturing facility from the previous supplier. The loss of this product severely limited a physician's ability to test for penicillin sensitivity. In 2005, AllerQuest was formed to resurrect production of PRE-PEN® so that allergy specialists and hospitals could again have a skin test for penicillin sensitivity.

Jose A. Moreno Toscano, President of ALK-Abelló, Inc., stated, "ALK is excited to be the exclusive provider of PRE-PEN®. Our focus continues to be in providing allergy specialists with unique products such as PRE-PEN®, and value added services to assist with fighting the cause of allergy and driving more patients to the specialist for proper diagnosis and treatment of allergic disease."

Dr. Louis Mendelson, President of AllerQuest, LLC stated, "More than 30 million Americans are suspected to be allergic to penicillin, but extensive studies have demonstrated that most of these people may be able to be treated safely with penicillin and related antibiotics. In past years, in the absence of a penicillin test, allergy specialists were unable to test patients for penicillin sensitivity. AllerQuest has invested significant time and resources to bring this important product back into the US market, and we are pleased to bring this product to market with a company like ALK, which possesses strengths in marketing and world-wide distribution critical to the successful re-launching of PRE-PEN®."

Additional information can be found at www.pre-pen.com.

About ALK
ALK is a research driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy) - a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Further information is available at www.alk-abello.us

About AllerQuest, LLC
AllerQuest's mission is to develop skin test reagents to safely and accurately identify patients who are at risk for potentially life-threatening reactions to penicillin antibiotics. The company strives to ensure a reliable source of high quality test reagents to assist physicians in the diagnosis of penicillin allergy. Further information is available at www.allerquest.com

###

Read the full story at http://www.prweb.com/releases/ALKAbello/PrePen/prweb2973314.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. FDA Approves Donor Screening Test for Antibodies to HIV
2. ClearWay Minnesota(SM) Board Approves New Officers
3. FDA Approves Vaccines for 2009 H1N1 Influenza Virus
4. FDA Approves 4 Swine Flu Vaccines
5. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
6. FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
7. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
8. First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Programs Viability
9. Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
10. FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
11. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 budget request ... shift more of the cost burden to military beneficiaries. , MOAA’s president, retired ... defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. ...
(Date:2/11/2016)... ... 2016 , ... In a new paper published in the ... Rod J. Rohrich, and colleagues, examine and underscore the importance of upper lateral ... when addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD CEO Robert ... will focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities ... practices in data breaches for the Part D Star Rating improvement and Medication ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced ... , will be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking ... During his session, “ Coding for Care: Using Data Analytics for Risk Adjustment ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical ... in the heart of Old Town at 108 South Columbus St, Suite 201, Alexandria, ... highest level of medical care in the convenience of their homes, offices or at ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 Transformational M&A achieved through NPS ... --> Transformational M&A achieved through NPS and Dyax ... Transformational M&A achieved through NPS and Dyax acquisitions ... for future growth with most robust pipeline in Shire ... future growth with most robust pipeline in Shire , ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... Exactus Pharmacy Solutions, a WellCare (NYSE: ... care for those suffering from long-term, life-threatening or ... Specialty Pharmacy Accreditation from URAC, an independent, nonprofit ... care quality through accreditation, education and measurement. ... URAC accreditation process demonstrates a commitment to quality ...
Breaking Medicine Technology: